Ardelyx (ARDX) has drawn fresh attention after recent trading, with the stock down 24% over the past month and 13% over the past 3 months, prompting investors to reassess its current valuation.

At a share price of US$5.40, Ardelyx has seen pressure in the short term, with the 7 day share price return down 13.6% and the 30 day return down 24.3%, while the 1 year total shareholder return of 48.4% reflects a stronger longer term outcome.

If recent volatility has you comparing opportunities in healthcare, it could be a good time to scan a curated list of 40 healthcare AI stocks

With Ardelyx trading at US$5.40, revenue of US$427.7 million, a reported net loss of US$58.06 million, and an analyst target of US$16.33, is the stock a genuine bargain, or is the market already pricing in future growth?

Most Popular Narrative: 66.9% Undervalued

Against a last close of US$5.40, the most followed narrative places Ardelyx's fair value at US$16.33, framing the recent pullback in a very different light.

The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

Want to see what underpins that US$16.33 fair value? The narrative leans heavily on rapid top line expansion, a sharp profit swing, and a richer future earnings multiple. The exact mix of those inputs might surprise you.

Result: Fair Value of US$16.33 (UNDERVALUED)

However, the story can change quickly if reliance on IBSRELA and XPHOZAH, or exposure to Medicare reimbursement and ongoing legal proceedings, begins to weigh more heavily.

Next Steps

With sentiment clearly split between risks and rewards, it makes sense to move quickly, review the data for yourself, and pressure test the narrative. To see the full list of potential upsides and areas of concern in one place, check out the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock when there are so many focused ways to hunt for opportunities that fit your goals and risk comfort.

• Target dependable income by scanning companies with strong payouts and resilient cash flows using the 10 dividend fortresses.
• Hunt for quality at a discount by checking the screener containing 22 high quality undiscovered gems before other investors catch on.
• Stand on steadier ground by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (46 results) so you are not relying on fragile finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.